HepaLife Technologies Inc. - Home Page
(Text Only)
Click for Press Releases
Sign up for investor alerts:
Cell-Based Medical Technologies
HepaLife Technologies Inc., (Symbol: HPLF) is a developer of cell-based medical technologies addressing prevalent human health concerns.
- Artificial liver device
We are working towards the first-of-its-kind bioartificial liver device using the patented liver stem cell line PICM-19 for acute liver failure. The HepaLife™ bioartificial liver, currently under development, is designed to serve as a supportive device, either allowing the liver to regenerate upon acute liver failure, or to bridge the patients's liver functions until a transplant is available.
- In-vitro toxicology testing platforms
Utilizing the patented liver stem cell line PICM-19, we are designing testing platforms to improve the pharmaceutical industry’s capability to evaluate drug toxicity and possible side-effects before pharmaceutical compounds are commercially distributed.
News
05/12/2008 - HepaLife’s Bioartificial Liver Exceeds Expectations in New Tests Conducted Over Prolonged Periods of Time
04/28/2008 - New Artificial Liver Tests: HepaLife’s ‘PICM-19’ Demonstrate Advantages Over Today’s Best-Available Liver Cells
04/16/2008 - HepaLife™ to Present Bioartificial Liver Device Data at International Stem Cell Conference
Animations
Click here for cross section of Hepalife's bioreactor (flash format: swf)
Click here for HepaLife's bioartificial liver circuit (flash format: swf)
^TOP